Burden of Vaccine-Preventable Diseases in People Living with HIV

Overview

Journal Vaccines (Basel)

Date 2024 Jul 27

PMID 39066418

Authors

Hady Samaha

Arda Yigitkanli

Amal Naji

Bahaa Kazzi

Ralph Tanios

Serena Maria Dib

Ighovwerha Ofotokun

Nadine Rouphael

Affiliations

Soon will be listed here.

Abstract

Vaccine-preventable diseases (VPDs) pose a serious public health concern for people living with HIV (PLH). PLH experience a delayed and weakened response to many vaccines available, compared to the general population. Lower seroconversion rates, along with a decreased efficacy and durability of vaccines, increases the susceptibility of PLH to VPDs. Vaccination guidelines specifically targeting this population have been modified to overcome these challenges. However, vaccine uptake remains suboptimal due to multiple barriers, highlighting the need for further studies and the additional implementation of public health measures specifically tailored to PLH.

Citing Articles

The Impact of HIV on B Cell Compartment and Its Implications for COVID-19 Vaccinations in People with HIV.

Wang L, Vulesevic B, Vigano M, Assadiq A, Kang K, Fernandez C Vaccines (Basel). 2025; 12(12.

PMID: 39772034 PMC: 11679862. DOI: 10.3390/vaccines12121372.

References

Kombe Kombe A, Li B, Zahid A, Mengist H, Bounda G, Zhou Y . Epidemiology and Burden of Human Papillomavirus and Related Diseases, Molecular Pathogenesis, and Vaccine Evaluation. Front Public Health. 2021; 8:552028. PMC: 7855977. DOI: 10.3389/fpubh.2020.552028. View

McPherson T, Ramirez E, Ringness M, Ruestow P, Marlow M, Fricchione M . Mumps Cases Disproportionately Affecting Persons Living with HIV Infection and Men Who Have Sex with Men - Chicago, Illinois, 2018. MMWR Morb Mortal Wkly Rep. 2020; 69(28):909-912. PMC: 7366853. DOI: 10.15585/mmwr.mm6928a3. View

Briere E, Rubin L, Moro P, Cohn A, Clark T, Messonnier N . Prevention and control of haemophilus influenzae type b disease: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2014; 63(RR-01):1-14. View

Redd S, Rutherford 3rd G, Sande M, Lifson A, Hadley W, Facklam R . The role of human immunodeficiency virus infection in pneumococcal bacteremia in San Francisco residents. J Infect Dis. 1990; 162(5):1012-7. DOI: 10.1093/infdis/162.5.1012. View

Kolobova I, Nyaku M, Karakusevic A, Bridge D, Fotheringham I, OBrien M . Burden of vaccine-preventable diseases among at-risk adult populations in the US. Hum Vaccin Immunother. 2022; 18(5):2054602. PMC: 9225203. DOI: 10.1080/21645515.2022.2054602. View

Geretti A, Doyle T . Immunization for HIV-positive individuals. Curr Opin Infect Dis. 2009; 23(1):32-8. DOI: 10.1097/QCO.0b013e328334fec4. View

DeGroote N, Mattson C, Tie Y, Brooks J, Garg S, Weiser J . Hepatitis A virus immunity and vaccination among at-risk persons receiving HIV medical care. Prev Med Rep. 2018; 11:139-144. PMC: 6040111. DOI: 10.1016/j.pmedr.2018.06.006. View

Mohareb A, Kim A . Hepatitis B Vaccination in People Living With HIV-If at First You Don't Succeed, Try Again. JAMA Netw Open. 2021; 4(8):e2121281. PMC: 8513073. DOI: 10.1001/jamanetworkopen.2021.21281. View

Stelzle D, Tanaka L, Lee K, Ibrahim Khalil A, Baussano I, Shah A . Estimates of the global burden of cervical cancer associated with HIV. Lancet Glob Health. 2020; 9(2):e161-e169. PMC: 7815633. DOI: 10.1016/S2214-109X(20)30459-9. View

10.

Pourcher V, Gourmelen J, Bureau I, Bouee S . Comorbidities in people living with HIV: An epidemiologic and economic analysis using a claims database in France. PLoS One. 2020; 15(12):e0243529. PMC: 7746269. DOI: 10.1371/journal.pone.0243529. View

11.

Rodriguez-Mendez M, Gonzalez-Quintela A, Aguilera A, Barrio E . Prevalence, patterns, and course of past hepatitis B virus infection in intravenous drug users with HIV-1 infection. Am J Gastroenterol. 2000; 95(5):1316-22. DOI: 10.1111/j.1572-0241.2000.01981.x. View

12.

Cooper C, Thorne A, Klein M, Conway B, Boivin G, Haase D . Immunogenicity is not improved by increased antigen dose or booster dosing of seasonal influenza vaccine in a randomized trial of HIV infected adults. PLoS One. 2011; 6(3):e17758. PMC: 3064575. DOI: 10.1371/journal.pone.0017758. View

13.

Atashili J, Kalilani L, Adimora A . Efficacy and clinical effectiveness of influenza vaccines in HIV-infected individuals: a meta-analysis. BMC Infect Dis. 2006; 6:138. PMC: 1574329. DOI: 10.1186/1471-2334-6-138. View

14.

French N, Gordon S, Mwalukomo T, White S, Mwafulirwa G, Longwe H . A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med. 2010; 362(9):812-22. PMC: 2873559. DOI: 10.1056/NEJMoa0903029. View

15.

King Jr J, Treanor J, Fast P, Wolff M, Yan L, Iacuzio D . Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults. J Infect Dis. 2000; 181(2):725-8. DOI: 10.1086/315246. View

16.

Gilsdorf J . Hib Vaccines: Their Impact on Haemophilus influenzae Type b Disease. J Infect Dis. 2021; 224(12 Suppl 2):S321-S330. PMC: 8482018. DOI: 10.1093/infdis/jiaa537. View

17.

Ssentongo P, Heilbrunn E, Ssentongo A, Advani S, Chinchilli V, Nunez J . Epidemiology and outcomes of COVID-19 in HIV-infected individuals: a systematic review and meta-analysis. Sci Rep. 2021; 11(1):6283. PMC: 7973415. DOI: 10.1038/s41598-021-85359-3. View

18.

Basoulis D, Mastrogianni E, Voutsinas P, Psichogiou M . HIV and COVID-19 Co-Infection: Epidemiology, Clinical Characteristics, and Treatment. Viruses. 2023; 15(2). PMC: 9962407. DOI: 10.3390/v15020577. View

19.

Lu P, Hung M, Srivastav A, Grohskopf L, Kobayashi M, Harris A . Surveillance of Vaccination Coverage Among Adult Populations -United States, 2018. MMWR Surveill Summ. 2021; 70(3):1-26. PMC: 8162796. DOI: 10.15585/mmwr.ss7003a1. View

20.

Sadlier C, ODea S, Bennett K, Dunne J, Conlon N, Bergin C . Immunological efficacy of pneumococcal vaccine strategies in HIV-infected adults: a randomized clinical trial. Sci Rep. 2016; 6:32076. PMC: 5007521. DOI: 10.1038/srep32076. View